In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
news
-
31-01-2018
Opening of an antitrust investigation
read more -
31-10-2017
Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma, and red blood cells
read more -
25-08-2017
Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®
The product is approved for post-exposure prophylaxis against rabies infection
read more -
11-08-2017
First half results 2017
First half consolidated turnover of EUR 271.7 M and adjusted EBITDA increase by 29.0% compared to the same period in 2016, with a margin of 24.1%
read more -
12-07-2017
Result of cash tender offer for Notes due 24 april 2019
The Company hereby announces to accept for purchase Notes validly tendered pursuant to the Offer for a total aggregate principal amount equal to €91,080,000
read more -
05-07-2017
Launch of new 350 Million Bond and tender offer indicative results
Kedrion successfully completed pricing of new Euro 350 M notes due July 2022 and tender offer for notes due April 2019
read more -
27-06-2017
Cash Tender Offer for Notes due 24 April 2019
Tender Offer for €300,000,000 4.625 per cent. Notes due 24 April 2019
read more -
31-03-2017
Annual Results 2016
Consolidated turnover of 659.3 million Euro, a growth of 89 million Euro or 15.6%
read more -
29-09-2015
Kedrion Notes 2019 Tender Offer results
Kedrion has decided to accept for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000
read more -
21-09-2015
Cash Tender Offer for Notes due 24 April 2019
Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019.
read more
Pages
For more information please contact: investor@kedrion.com
Where 